Relmada Therapeutics
RLMD
113 hedge funds and large institutions have $468M invested in Relmada Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 13 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 24
107% more capital inflows, than outflows
Capital inflows: $64.5M | Capital outflows: $31.2M
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
16% more call options, than puts
Call options by funds: $29.1M | Put options by funds: $25.2M
3.72% more ownership
Funds ownership: 78.58% → 82.3% (+3.7%)
0% more funds holding
Funds holding: 113 → 113 (0)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
+$8.72M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
+$8.68M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.2M |
| 4 |
BlackRock
New York
|
+$4.36M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mangrove Partners
Greenwich,
Connecticut
|
-$6.97M |
| 2 |
ACM
Altium Capital Management
New York
|
-$3.88M |
| 3 |
MPM BioImpact
Boston,
Massachusetts
|
-$3.72M |
| 4 |
Millennium Management
New York
|
-$3.51M |
| 5 |
Cowen and Company
New York
|
-$2.13M |
RLMD Hedge Fund Activity: Q2 2022 in Review
113 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2022, worth a combined $468M — down 25% from $623M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RLMD positions and 13 closed out — a net gain of 3 holders — while 50 added to existing stakes and 24 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $8.72M. The largest seller was Mangrove Partners, exiting entirely with an estimated $6.97M sold.
- 113 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $468M of Relmada Therapeutics stock for Q2 2022, down 25% quarter-over-quarter.
- 16 funds opened new Relmada Therapeutics positions in Q2 2022 and 13 closed out, a net change of +3 holders.
- The largest Relmada Therapeutics buyer in Q2 2022 was Tang Capital Management, an estimated $8.72M added.
- The largest Relmada Therapeutics seller in Q2 2022 was Mangrove Partners, an estimated $6.97M sold.
Based on aggregated 13F filings for Q2 2022.